Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said ...